SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 2
    Meyer RM, Browman GP, Samosh ML, et al. Randomized Phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol. 1995; 13: 23862393.
  • 3
    Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995; 13: 25302539.
  • 4
    Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998; 16: 2734.
  • 5
    Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood. 1988; 71: 117122.
  • 6
    Salar A, Martino R, Perea G, et al. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma. Haematologica. 2002; 87: 10281035.
  • 7
    Sparano JA, Weller E, Nazeer T, et al. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002; 100: 16341640.
  • 8
    Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol. 2002; 49(Suppl 1): S13S20.
  • 9
    Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 37763785.
  • 10
    Gisselbrecht C, Mounier N. Improving second-line therapy in aggressive non-Hodgkin's lymphoma. Semin Oncol. 2004; 31(1 Suppl 2 ): 1216.
  • 11
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333: 15401545.
  • 12
    [No authors listed.] A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987994.
  • 13
    La Barbera EO, Chiusolo P, Laurenti L, et al. MiCMA: an alternative treatment for refractory or recurrent Hodgkin's disease. Ann Oncol. 2000; 11: 867871.
  • 14
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 15
    Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003; 21: 12551262.
  • 16
    Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997; 336: 12901297.
  • 17
    Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004; 350: 12871295.
  • 18
    Philip T, Gomez F, Guglielmi C, et al. Long outcome of relapsed non-Hodgkin's lymphoma (NHL) patients included in the Parma trial: incidence of late relapses, long term toxicity and impact of the International Prognostic Index (IPI) at relapse [abstract]. Proc Am Soc Clin Oncol. 1988; 17: 16a.
  • 19
    Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the Parma trial. Parma Group. Blood. 1998; 92: 35623568.
  • 20
    Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004; 103: 36843688.
  • 21
    Moskowitz CH, Nimer SD, Glassman JR, et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant. 1999; 23: 561567.